MX2009011228A - Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento. - Google Patents

Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.

Info

Publication number
MX2009011228A
MX2009011228A MX2009011228A MX2009011228A MX2009011228A MX 2009011228 A MX2009011228 A MX 2009011228A MX 2009011228 A MX2009011228 A MX 2009011228A MX 2009011228 A MX2009011228 A MX 2009011228A MX 2009011228 A MX2009011228 A MX 2009011228A
Authority
MX
Mexico
Prior art keywords
cancer cells
neu
treatment
detection
neu protein
Prior art date
Application number
MX2009011228A
Other languages
English (en)
Spanish (es)
Inventor
Robert M Lorence
Ming Lu
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Publication of MX2009011228A publication Critical patent/MX2009011228A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009011228A 2007-04-19 2008-04-15 Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento. MX2009011228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91283307P 2007-04-19 2007-04-19
PCT/US2008/060317 WO2008130910A1 (en) 2007-04-19 2008-04-15 Detection her-2/neu protein from non-isolated circulating cancer cells and treatment

Publications (1)

Publication Number Publication Date
MX2009011228A true MX2009011228A (es) 2009-11-02

Family

ID=39875858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011228A MX2009011228A (es) 2007-04-19 2008-04-15 Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.

Country Status (7)

Country Link
US (1) US20100120072A1 (enExample)
EP (1) EP2145188A4 (enExample)
JP (1) JP2010525326A (enExample)
CN (1) CN101663584A (enExample)
CA (1) CA2684265A1 (enExample)
MX (1) MX2009011228A (enExample)
WO (1) WO2008130910A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
CN104122394A (zh) * 2013-04-23 2014-10-29 北京豪迈生物工程有限公司 人表皮生长因子受体2(Her-2)定量测定试剂盒及其检测方法
JP6245147B2 (ja) * 2014-11-19 2017-12-13 株式会社オートネットワーク技術研究所 モールド部付電線
CN104568923A (zh) * 2014-12-01 2015-04-29 浙江省肿瘤医院 电化学发光检测外周血循环肿瘤细胞抗原的方法及试剂盒
JP6323317B2 (ja) * 2014-12-09 2018-05-16 株式会社オートネットワーク技術研究所 端子付電線

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451225B1 (en) * 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6448091B1 (en) * 1988-11-03 2002-09-10 Igen International, Inc. Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
NO180658C (no) * 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner
AU2365895A (en) * 1994-04-26 1995-11-16 Regents Of The University Of Michigan, The Unitary sandwich enzyme immunoassay cassette, device and method of use
US5744367A (en) * 1994-11-10 1998-04-28 Igen International, Inc. Magnetic particle based electrochemiluminescent detection apparatus and method
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
CA2223027A1 (en) * 1995-06-07 1996-12-19 Igen, Inc. Electrochemiluminescent enzyme immunoassay
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6190870B1 (en) * 1995-08-28 2001-02-20 Amcell Corporation Efficient enrichment and detection of disseminated tumor cells
US6297062B1 (en) * 1996-03-07 2001-10-02 Bio-Magnetics Ltd. Separation by magnetic particles
US6890426B2 (en) * 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
EP1062515B1 (en) * 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US6300143B1 (en) * 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
US6969615B2 (en) * 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
JP3313107B2 (ja) * 2001-03-22 2002-08-12 バイエル コーポレイション ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
DE10143776A1 (de) * 2001-09-06 2003-04-03 Adnagen Ag Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs
CA2462914A1 (en) * 2001-10-11 2003-04-17 Aviva Biosciences Corporation Methods, compositions, and automated systems for separating rare cells from fluid samples
EP1597353B1 (en) * 2003-02-27 2010-11-24 Veridex, LLC CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS
JP4798801B2 (ja) * 2004-10-06 2011-10-19 ウェルスタット バイオロジクス コーポレイション 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
EP1816477A1 (en) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
CA2647843A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of proteins from circulating neoplastic cells
EP2008103B1 (en) * 2006-04-18 2010-07-28 Wellstat Biologics Corporation Detection of circulating endothelial cells
CA2647743A1 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of steroid receptors on circulating carcinoma cells and treatment

Also Published As

Publication number Publication date
JP2010525326A (ja) 2010-07-22
CA2684265A1 (en) 2008-10-30
EP2145188A1 (en) 2010-01-20
EP2145188A4 (en) 2010-06-30
WO2008130910A1 (en) 2008-10-30
US20100120072A1 (en) 2010-05-13
CN101663584A (zh) 2010-03-03

Similar Documents

Publication Publication Date Title
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
EP1797431A4 (en) DETECTION OF HIGH HER-2 / NEU PROTEIN RATES ON CIRCULATING CANCER CELLS AND TREATMENT THEREOF
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
EP3750916A3 (en) Anti-dengue virus ns1 protein monoclonal antibodies
AU2018261622A1 (en) Diagnostic advanced glycation end-product antibodies
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
MA33747B1 (fr) Anticorps monoclonaux diriges contre la progastrine et leurs utilisations
EP3208617A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2209495A4 (en) TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2569635A4 (en) METHOD FOR DIAGNOSIS AND / OR TREATMENT OF ENZEPHALITIS OR EPILEPSY
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
NZ609824A (en) Immunochromatography devices, methods and kits
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
WO2016198833A3 (en) Methods for analysing a urine sample
ZA202100296B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
MX369610B (es) Metodos, dispositivos y sistemas para analisis de muestras.
WO2015057968A3 (en) Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
Guidetti et al. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR

Legal Events

Date Code Title Description
FG Grant or registration